Zachariah DeFilipp, MD

Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).

There are many ideas that if followed will not just help you to "do your time" during fellowship, but contribute to the internal medicine residency program.